ISOPP 2019 Interview: Potential role of rituximab in mCRPC


Date posted:
October 2019
Date resource created:
October 10, 2019
Symposium: Research
Content Type:
Symposium (International)
File type:
Video (Interview)
Lisa Holle

Lisa Holle, PharmD, BCOP, FHOPA, University of Connecticut School of Pharmacy, Storrs, CT, reviews a recent case study of a patient with castrate-resistant prostate cancer who responded to treatment for a secondary folliular lymphoma following treatment with rituximab. This interview took place at the International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium 2019, hosted by the British Oncology Pharmacy Association (BOPA), held in London, UK.